Crinetics Pharmaceuticals (CRNX) 44th Annual J.P. Morgan Healthcare Conference summary

Business and Commercial Highlights

• Achieved approval and successful launch of Palsinify (paltusotine) for acromegaly, with over 200 patients enrolled, strong prescriber adoption, and over $5 million in preliminary Q4 2025 net product revenue.

• Built a fully integrated pharmaceutical company with robust infrastructure, commercial operations, and R&D, supported by approximately $1.4 billion in cash and investments as of January 2026, providing runway through 2030.

• Strategic partnerships and spinouts include licensing paltusotine in Japan and collaborations in animal health, radiopharmaceuticals, and technology out-licensing.

• Extensive patient support services and Quick Start program facilitate access and adherence, with payer acceptance and most prior authorizations granted for 12 months.

• Positive patient testimonials highlight meaningful impact of PALSONIFY, improving quality of life for those with acromegaly.

Pipeline and Clinical Development

• Advanced late-stage pipeline includes paltusotine for acromegaly and carcinoid syndrome, atumelnant for adult and pediatric CAH and ACTH-dependent Cushing's syndrome, and CRN09682 for neuroendocrine tumors.

• Phase 3 trials underway for paltusotine in carcinoid syndrome and atumelnant in adult CAH, with pediatric CAH trial planned for 1H2026; Phase 1/2 underway for CRN09682.

• Paltusotine showed positive Phase 2 data in carcinoid syndrome, reducing flushing and bowel movement frequency, and is being evaluated in a Phase 3 trial.

• Atumelnant demonstrated robust efficacy and safety in Phase 2, with up to 80% reduction in A4 biomarker and no serious or severe treatment-related adverse events.

• CRN09682, a novel small molecule targeting SST2, showed promising preclinical results and entered Phase 1/2 for neuroendocrine tumors.

Growth Strategy and Market Access

• Focused on expanding prescriber base and patient activation, especially among untreated and undiagnosed acromegaly patients.

• Real-world data and patient ambassador programs to drive awareness and adoption, with ongoing efforts to improve diagnosis rates and broaden market reach for Palsinify.

• No plans to discount to commercial payers; gross to net driven by payer mix and 340B institution participation.

• Achieved payer acceptance, with CVS Caremark adding Palsinify to formulary.